Abstract：
The fusion gene ZMIZ1-ABL1 is rare, with only one known case reported in lymphatic system malignancies, and none reported in a myeloid tumor. Here, we report the case of a patient with chronic myelomonocytic leukemia with the ZMIZ1-ABL1 fusion gene. Elevated leukocytes and splenomegaly were the main manifestations. Remission was achieved with the second-generation tyrosine kinase inhibitor (TKI) dasatinib, and the response has been sustained for 10 months. The treatment results in this case suggest that dasatinib is effective in treating ZMIZ1-ABL1 fusion gene-positive disease.
摘要：
融合基因ZMIZ1-ABL1是罕见的，只有一例已知的淋巴系统恶性肿瘤报告，没有骨髓性肿瘤的报道。这里,我们报道了一例携带ZMIZ1-ABL1融合基因的慢性粒单核细胞白血病患者。主要表现为白细胞升高和脾肿大。第二代酪氨酸激酶抑制剂（TKI）达沙替尼实现缓解，反应已经持续了10个月。这种情况下的治疗结果表明，达沙替尼可有效治疗ZMIZ1-ABL1融合基因阳性疾病。
